arithmos— AI-powered custom index builder. You’re viewing a shared index.
Index
Psychedelic Medicine Breakthrough Index
official“An index of clinical-stage biotech companies developing psychedelic-assisted therapies for depression, PTSD, and addiction — a nascent sector that could disrupt the $500B mental-health drug market.” — by Kelechi Vance
built · 2026-04-30 22:12·rebalance · semiannual·next run · 2026-10-30
backtest · S&P 500 (SPX)·range
CAGR—
Annual vol—
Sharpe—
Sortino—
Max drawdown—
Best year—
Worst year—
risk-free raterf = 4.50%
vs S&P 500 (SPX) · 1M—
vs S&P 500 (SPX) · 1Y—
vs S&P 500 (SPX) · 2Y—
vs S&P 500 (SPX) · 3Y—
vs S&P 500 (SPX) · 5Y—
vs S&P 500 (SPX) · 10Y—
no backtest data
sharpe ratio
| ticker | weight | YTD | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|
| CMPS | 14.0% | — | — | — | — | — |
| MNMD | 13.0% | — | — | — | — | — |
| ATAI | 12.0% | — | — | — | — | — |
| CYBN | 11.0% | — | — | — | — | — |
| LVTX | 11.0% | — | — | — | — | — |
| NUMI | 10.0% | — | — | — | — | — |
| TRYP | 10.0% | — | — | — | — | — |
| MNTV | 9.0% | — | — | — | — | — |
| DELI | 6.0% | — | — | — | — | — |
| MEDS | 4.0% | — | — | — | — | — |
| weighted | 100% | — | — | — | — | — |
attribution factsheet
holdings · 10
click a row to drill in ↗NameAllocationRationale
CMPSCOMPASS PathwaysHealthcare14.00%Furthest-along psilocybin company; Phase 3 for treatment-resistant depression underway.MNMDMindMedHealthcare13.00%LSD analog MM-120 in Phase 2b for anxiety; strong IP portfolio.ATAIatai Life SciencesHealthcare12.00%Thiel-backed platform holding company with 10+ psychedelic pipeline assets.CYBNCybinHealthcare11.00%Deuterated psilocybin analogue CYB003 in Phase 2 for MDD; fast-acting formulation.LVTXLAVA TherapeuticsHealthcare11.00%Bispecific oncology + ketamine adjacency platform.NUMINuminus WellnessHealthcare10.00%Ketamine clinic operator and MDMA trial site; services + pipeline.TRYPTryp TherapeuticsHealthcare10.00%Psilocybin for eating disorders and fibromyalgia; differentiated indication strategy.MNTVMentavationHealthcare9.00%Digital therapeutic wrap-around care for psychedelic sessions.DELIDeliver My DoseHealthcare6.00%Specialty pharmacy logistics for Schedule I/II psychedelic clinical trials.MEDSTRxADE HealthHealthcare4.00%B2B pharma marketplace positioning for psychedelic prescription distribution.
weighting · equal
rebalance · semiannual
